PMID- 27951719
OWN - NLM
STAT- MEDLINE
DCOM- 20170606
LR  - 20191113
IS  - 0862-495X (Print)
IS  - 0862-495X (Linking)
VI  - 29
IP  - 6
DP  - 2016 Winter
TI  - [Molecular Genetic Testing for Acute Myeloid Leukemia].
PG  - 411-418
AB  - BACKGROUND: Acute myeloid leukemia (AML) is a clinically complex and very 
      heterogeneous disease at the molecular level. Conventional cytogenetic analysis 
      and FISH (fluorescence in situ hybridization) tests provide important information 
      about the biological and clinical background of the disease and enable the 
      classification of AML patients into three risk groups. However, up to half of 
      patients have normal cytogenetics. Determining prognosis and treatment strategies 
      in this group of patients is challenging. The development of molecular genetic 
      methods, including next generation sequencing in the last decade, has led to the 
      discovery of a number of recurrent mutations that have contributed to increasing 
      the accuracy of prognosis of those patients with cytogenetically normal AML. 
      Besides the prognostic value of these mutations, they may also be used to monitor 
      minimal residual disease during and after treatment of AML and additionally 
      constitute potential targets for the development of new therapeutic agents. The 
      importance of molecular genetic testing of all patients with AML is highlighted 
      by the WHO classification of 2008 in which subgroups of AML are purely defined by 
      molecular genetics markers. AIM: In this article, we provide an overview of the 
      most significant mutations in patients with cytogenetically normal AML. We 
      describe their significance for prognosis, their importance in monitoring minimal 
      residual disease, and their potential for the development of new targeted 
      therapies. Further, we briefly draw attention to the significance of gene 
      mutation accumulation in clonal disease development and how it affects the time 
      of AML relapse.
FAU - Janeckova, V
AU  - Janeckova V
FAU - Semerad, L
AU  - Semerad L
FAU - Jeziskova, I
AU  - Jeziskova I
FAU - Dvorakova, D
AU  - Dvorakova D
FAU - Culen, M
AU  - Culen M
FAU - Sustkova, Z
AU  - Sustkova Z
FAU - Mayer, J
AU  - Mayer J
FAU - Racil, Z
AU  - Racil Z
LA  - cze
PT  - Journal Article
PT  - Review
TT  - Molekularne geneticke vysetreni u akutni myeloidni leukemie.
PL  - Czech Republic
TA  - Klin Onkol
JT  - Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
JID - 9425213
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers
MH  - DNA Mutational Analysis
MH  - Genetic Testing
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/*genetics
MH  - Prognosis
MH  - Recurrence
OTO - NOTNLM
OT  - Brno MUNI/A/1028/2016.The authors declare they have no potential conflicts of 
      interest concerning drugs
OT  - acute myeloid leukemia - genetics - mutation - prognosis - minimal residual 
      disease - clonal evolutionThis work was supported by the program project of the 
      Czech Ministry of Health reg. No. 15-25809A and by the project of Masaryk 
      University
OT  - products or services used in the study.The Editorial Board declares that the 
      manuscript met the ICMJE recommendation for biomedical papers.Submitted: 8. 9. 
      2016Accepted: 30. 9. 2016.
EDAT- 2016/12/14 06:00
MHDA- 2017/06/07 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [entrez]
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2017/06/07 06:00 [medline]
AID - 59859 [pii]
AID - 10.14735/amko2016411 [doi]
PST - ppublish
SO  - Klin Onkol. 2016 Winter;29(6):411-418. doi: 10.14735/amko2016411.